Find a Clinical Trial
Filter
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Breast cancer, Locally advanced and metastatic breast cancer
All genders
Recruiting now
Cancer Center
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Breast Cancer Database
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
All genders
Recruiting now
Cancer Center
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast cancer
All genders
Recruiting now
Cancer Center
An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Exploring the Role of the Mineralocorticoid Receptor in Human Vascular Disease
Vascular diseases
All genders
Recruiting now
Department of Surgery, Division of Vascular Surgery
HER2 Negative Breast Cancer
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Breast cancer
All genders
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
BCL Study
Breast cancer
Female
Recruiting now
Department of Surgery